Insilico Medicine Reports 40% ORR for ISM6331 at 130 mg
Insilico Medicine reported a 40% objective response rate at 130 mg for its pan-TEAD inhibitor ISM6331 in heavily pretreated mesothelioma at ESMO 2026.
Insilico Medicine reported a 40% objective response rate at 130 mg for its pan-TEAD inhibitor ISM6331 in heavily pretreated mesothelioma at ESMO 2026.